Clinical Trials Logo
  1. Home
  2. Guillain-Barre Syndrome
  3. NCT02221271

Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

Guillain-Barré Syndrome Clinical Trial

Clinical Trial Summary

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.

Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02221271
Study type Interventional
Source Nihon Pharmaceutical Co., Ltd
Contact
Status Completed
Phase Phase 3
Start date October 2014
Completion date August 2015
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05494619 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Phase 3
Withdrawn NCT03773328 - A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) Phase 1
Active, not recruiting NCT01582763 - International Guillain-Barré Syndrome Outcome Study
Completed NCT04035135 - A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) Phase 1
Recruiting NCT05461898 - RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome N/A
Completed NCT02780570 - Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Phase 2
Completed NCT02342184 - Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Phase 3